Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
In a proportion of patients with AL amyloidosis there is no improvement of cardiac function
despite hematologic response to treatment. The aim of the study is to assess whether
treatment with EGCG increases the rate of cardiac response in patients with AL amyloidosis
who completed chemotherapy.